U.S. agency rejects Teva bid to extend patent on Copaxone
Four of Teva's patents on flagship multiple sclerosis drug set to expire next month.
The U.S. Patent Office on Friday rejected a request by Teva Pharmaceutical Industries to extend one of several patents on its flagship multiple sclerosis drug, Copaxone.
register with haaretz
Like us on Facebook and get articles directly in your news feed